APRINOIA Therapeutics

APRINOIA Therapeutics is a clinical-stage biotechnology company focused on discovering and developing diagnostics and therapeutics for Alzheimer's Disease (AD) and other tau-associated neurodegenerative diseases, known as tauopathies. The company operates in the healthcare and biotechnology market, serving patients, research institutions, and pharmaceutical companies. APRINOIA's business model involves building comprehensive internal drug discovery and development capabilities, as well as forming integrative collaborations with world-class scientists and research institutions. The company generates revenue through licensing agreements, such as its non-exclusive licensing agreement with Celgene Corporation for the use of its novel investigational PET imaging tracer, APN-1607. APRINOIA's pipeline includes diagnostic imaging tracers, monoclonal antibodies (mAbs) specific to pathologic tau, and small molecules that bind to tau. The company aims to develop imaging biomarkers to visualize therapeutic targets and subsequently create treatments to address these targets.

Keywords: Alzheimer's, tauopathies, diagnostics, therapeutics, PET imaging, biomarkers, monoclonal antibodies, small molecules, neurodegenerative, biotechnology.